2019
DOI: 10.1590/s0004-2803.201900000-58
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BACKGROUND: There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America. OBJECTIVE: To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients. METHODS: Retrospective observational multicentric study of patients with Crohn’s disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw ind… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 29 publications
0
5
0
Order By: Relevance
“…To date, there are no descriptions of frequencies of patients using these new agents in full cohort studies in Latin America. However, some initial experiences with the drugs are starting to be described, mostly in abstract form presented in recent IBD meetings (41)(42)(43)(44) .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To date, there are no descriptions of frequencies of patients using these new agents in full cohort studies in Latin America. However, some initial experiences with the drugs are starting to be described, mostly in abstract form presented in recent IBD meetings (41)(42)(43)(44) .…”
Section: Resultsmentioning
confidence: 99%
“…An initial Brazilian experience with 90 patients (52 with CD and 38 with UC using vedolizumab (VEDO), an anti-integrin agent, was described in 2018 (41,42) . Clinical remission rates in CD after 52 weeks of treatment were 46.15% and 24.48% in as observed and NRI (non-responder imputation) analyses, respectively.…”
Section: Resultsmentioning
confidence: 99%
“…Real-world MH rate ranges were 20.0%-22.2% at 3 months (mean ± SD, 21:3% ± 1:2%; three studies [37][38][39]), 10.1%-46.0% at 6 months (mean ± SD, 30:4% ± 11:8%; ten studies [29,30,[39][40][41][42][43][44][45][46]), and 21.2%-62.5% at 12 months (mean ± SD, 37:8% ± 14:6%; eight studies [28,37,39,43,[47][48][49][50][51]). Cumulative 12-month MH rates were 54%-62.5% in anti-TNF-naïve patients (two studies [28,49]) and 47%-59.7% in anti-TNF-experienced patients [28,49].…”
Section: Statistical Analysesmentioning
confidence: 99%
“…anti-TNF: antitumour necrosis factor; GI: gastrointestinal; SES-CD: Simple Endoscopic Score for Crohn's Disease. † Four studies (Kotze et al[39]; Ylisaukko-Oja et al[46]; Perin et al[42]; Reinglas et al[58]) reported mean age and standard deviation. ‡ Three studies (Kotze et al[39]; Amiot et al[70]; Wang et al[71]) reported mean age at diagnosis and standard deviation.…”
mentioning
confidence: 99%
“…In view of the therapeutic management of IBDs, the introduction of anti-TNF agents has positively marked this path[ 81 - 83 ], especially as they favor the healing of the mucosal layer with increases in its growth with stimulation[ 84 ], and as they demonstrate a greater safety of use when compared to conventional protocols[ 81 , 82 ]. In this same context, the P2X7 receptor is also emerging as a very important medical target for the prevention and treatment of these disorders[ 10 ], possibly in a similar way to the above, since its continuous activation may worsen the local inflammatory response[ 85 , 86 ].…”
Section: Inflammatory Bowel Diseases and Their Impacts On The Enteric Nervous Systemmentioning
confidence: 99%